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and gender, including physician visits, pain-clinic visits, neurology-clinic visits,
and ED visits. In the 75-84 years age group, frequency of utilization was higher by
22%, 39%, 45% and 48% for these health care resources, respectively.
CONCLUSIONS: Epidemiology of HZ in Israel is similar to that reported for other
countries. This illness presents a burden on the elderly population and is related
with increased resource utilization.
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OBJECTIVES: To quantify the economic effects of an in-vitro-fertilization (IVF) born
persons in terms of productivity gains and net tax revenues for the state in Greece.
METHODS:A mathematical model was developed to assess the lifetime productiv-
ity and transactions between an individual and the governmental agencies. The
model distinguishes amongst three periods in economic life cycle: 1) early life,
when the government primarily contributes resources through child tax credits,
health care, and educational expenses; 2) employment, when individuals begin
returning resources through taxes; and 3) retirement, when the government ex-
pends additional resources on Social Security and old-age programs. Cost of life
birth with IVF was based on a modification of a previous published model devel-
oped by the authors. All outcomes were discounted at a 3% discounting rate. The
data inputs, namely the economic or demographic variables, were derived from
National Statistical Secretariat of Greece and other relevant sources. To deal with
uncertainty, bias corrected uncertainty intervals (UI) was calculated based on 5000
Monte Carlo simulations. In addition, to examine the robustness of our results,
other one-way sensitivity analyses were also employed. RESULTS: The cost of IVF
per birth was estimated at €17,078 (95%UI: €16,350-€17,805). The average projected
income generated by an individual throughout his productive life, was €667,651
(95%UI: €538,897-€762,862). In addition, his life tax contribution was estimated at
€200,295 (95%UI: €168,669-228,670), while the discounted governmental expenses
for elderly and underage individuals were at €36,570 (95%UI: €33,614-€40,463).
Hence, the net present value of IVF was €163,726 (95%UI: €124,533-€192,215) repre-
senting a 547% net return on investment. Results remained constant under various
assumptions for the main model parameters. CONCLUSIONS: State-funded IVF
represents good value for money in the Greek setting, as it has positive tax benefits
for the government, notwithstanding its beneficial psychological effect for infertil-
ity couples and the overall productivity gains.
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Infections are a major contributor to neonatal mortality and morbidity levels all
over the world. OBJECTIVES: To assess clinical efficacy and cost-effectiveness of
additional immunotherapy in neonates with severe infections in neonatal inten-
sive care unit (NICU). METHODS: We observed 375 neonates (gestational age (GA)
25-41 weeks) with severe early-onset infections in NICU. Fifty-two neonates with
hypogammaglobulinemia were treated with normal human immunoglobulin
(NHI), 85 newborn infants with lymphopenia were treated with human interleukin
2 (HI2), 94 neonates with low mitogen-induced interferon- production treated
with interferon-2b. A total of 144 were under standard treatment without addi-
tional immunotherapy. RESULTS: Administration of NHI resulted in reduction of
NICU length of stay and mortality level in cases of septic shock - 7.1% [0.2%; 34%] vs
40% in a similar group without immunosubstitutive therapy (p0.05). Administra-
tion of interferon-2b reduces hospital length of stay and mortality rates (g0.009,
OR  0.21 [0.05; 0.67], RR  0.26 [0.07; 0.69], NNT8 [4; 29]). Administration of HI2
reduces NICU length of stay and mortality rates from severe infection (g0.047;
OR0.36 [0.13; 0.98]; RR0.41 [0.17; 0.98]; NNT9 [4; 214]). Administration of immu-
notherapy in early-onset neonatal infections leads to substantial cost savings up to
€ 168,896 per patient in case of NHI treatment, € 60,910 per patient in case of HI2
treatment and € 69, 247 per patient in case of interferon-2b administration.
CONCLUSIONS: Additional immunotherapy in early-onset neonatal infections is a
cost-effective intervention that allows to reduce mortality rates and save money.
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OBJECTIVES: To investigate the cost effectiveness of intermittent treatment of
PMDD (premenstrual dysphoric disorder) with Premalex (escitalopram) 20 mg com-
pared with sertraline 50-100 mg based upon the Clinical Global Impressions – Se-
verity (CGI-S), from a societal perspective. METHODS: We identified one ran-
domised placebo controlled trial with sertraline and one with Premalex, reporting
the CGI-S as an outcome. Using placebo, the CGI-S was used to make an indirect
effect comparison between Premalex and sertraline. The CGI-S was translated into
QALY weights, through the proportion of time spent with a high degree of the
anxiety/depression in the EQ-5D. Costs of health care visits were estimated using a
local treatment pattern survey among GPs and gynaecologists. Official drug prices
were used. A Premalex dose of 15 mg, the average of 10 and 20 mg, was assumed as
it is stated in the SPC text that many of the patients will benefit from 10 mg. 37-75%
lower drug costs were used in years 2-3 due to expected generic competition.
Indirect costs were estimated using a published international study of the effect of
PMDD on sick leave and productivity. A societal perspective was taken over a 3-year
time frame. RESULTS:During the first year, Premalex treatment increased drug costs
(SEK 1599), partly offset by indirect costs saving (SEK 1413), resulting in a total cost of
SEK 186, compared to sertraline. An estimated gain of 0.0044 QALYs with Premalex
compared to sertraline gave an incremental cost per QALY gained of SEK 42200 (EUR
4700). In the next 2 years, drug costs were more than offset by indirect costs saving,
leading to an overall gain of 0.0132 QALYs and a savings of SEK 1600 per three years
with Premalex compared to sertraline.CONCLUSIONS: Treatment of PMDD with Pre-
malex is cost effective compared to sertraline, from a societal perspective.
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OBJECTIVES:A very recent Meta-Analysis shows that the addition of Omega-3 fatty
acid in standard Total Parenteral Nutrition (TPN) is associated with reductions in
infection rate, ICU, and overall lengths of stay (LOSs) for both Intensive Care Unit
(ICU) and elective surgery patients. Aim of this study is the CE analysis of its use in
these patient populations, as compared to standard lipid emulsions. METHODS:
Within a Discrete Event Simulation (DES) scheme, a patient-level simulation model
was developed, with the inclusion of baseline outcomes rates from the Italian ICU
patient population and from published literature; comparative efficacy data for
standard and Omega-3 fatty acids-based regimens from the meta-analysis of pub-
lished randomized clinical trials (conducted on 23 studies with a total of 1502
patients), and country-specific cost data. Clinical outcomes included in the model
are death rates, nosocomial infection rates, and ICU/hospital LOSs. Costs are re-
ferred to Italian, French German and UK health care systems. Probabilistic and
deterministic sensitivity analyses are undertaken to test results’ reliability.
RESULTS:Omega-3 fat emulsions emerged as more effective on average than stan-
dard TPN both in ICU and in non-ICU patients: in all the four national contexts here
considered, reduced mortality rates, infection rates, and overall LOSs yield a lower
total cost per patient. Treatment costs are completely offset by the reduction in
hospital stay costs and antibiotic costs. Sensitivity analyses confirmed the robust-
ness of these findings. CONCLUSIONS: These results indicate that the addition of
Omega-3 to standard TPN is expected to improve clinical outcomes and concur-
rently give a saving for Italian, French, German and UK hospitals.
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OBJECTIVES: LNG-IUS 12 is a novel intrauterine contraceptive system for up to 3
years use with an average in vitro release rate of 12g of levonorgestrel per day.
This study was conducted to estimate the relative cost-effectiveness of LNG-IUS 12
versus short-acting reversible contraception (SARC) in the United States from a
third-party payer’s perspective. METHODS: A Markov model was constructed to
compare the effectiveness and costs of LNG-IUS 12 and SARC over a 3-year period
in a cohort of 1000 women aged 20 to 29 years, the age group in which most
unplanned pregnancies occur. SARC methods comprise contraceptives commonly
used by this age cohort, including oral contraceptives, the ring, the patch and
injections. Primary health states included initial/continued use of contraceptive
method and method failure (unplanned pregnancies). The impact of switching
methods was also incorporated into the model and tested through sensitivity anal-
ysis. Estimates for probabilities of failure and discontinuation, resource utilization
and costs were derived from a comprehensive literature review, average wholesale
drug prices and the 2012 Medicare Reimbursement Fee Schedule, respectively. Cost
and effectiveness metrics for SARC were calculated as weighted averages using
distribution of use data for SARC. One-way sensitivity analyses were performed on
all key variables. RESULTS: LNG-IUS 12 dominated SARC in women aged 20 to 29
years, resulting in fewer unplanned pregnancies (9.86 vs. 238.75) and lower total
costs ($930,187USD vs. $1,528,163USD, a 39% saving) over 3 years. The cost of con-
traception and number of unplanned pregnancies associated with SARC were key
model drivers. Results were insensitive to variation in key input values during
one-way sensitivity analyses. CONCLUSIONS: From a third-party payer perspec-
tive, LNG-IUS 12 is a more cost-effective contraceptive option than SARC. Addi-
tional analysis of discontinuation patterns and planned pregnancy events within
future model extensions will help to further reflect real-life utilization pattern.
PIH22
CLINICAL EFFICACY AND COST-EFFECTIVENESS OF HUMAN RECOMBINANT
INTERFERON-2B IN NEONATAL INFECTIONS
Soldatova I1, Pankratyeva L2
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National
Research Medical University, Moscow, Russia, 2Russian National Research Medical University,
Moscow, Russia
A539V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
